NewsWednesday, 28 Jan 2026Help us raise $3,000 to support Glaucoma NZ
We’re taking part in Round the Bays Auckland 2026 to help raise essential funds for the important work of Glaucoma New Zealand.
Auckland Eye has become the very first site worldwide to recruit and treat a patient in the i-SIGHT2 study.
The i-SIGHT2 trial, sponsored by i-Lumen Scientific, is a multi-centre clinical study evaluating an exciting new approach for patients suffering vision loss due to intermediate or late-stage dry age-related macular degeneration (AMD).
Dry AMD is one of the leading causes of vision impairment in older adults, and until now, treatment options have been extremely limited. The i-SIGHT2 study represents an innovative effort to change this landscape by investigating whether targeted retinal stimulation can help preserve or improve vision for patients living with this condition.
Being the first centre globally to initiate treatment highlights both Auckland Eye’s commitment to advancing ophthalmic research and the dedication of our team to bringing innovative therapies closer to patients in New Zealand.
News
Monday, 22 Sep 2025
Read More
NewsWednesday, 28 Jan 2026
NewsMonday, 6 Oct 2025CoMpass Clinical Trial 2025
Auckland Eye is proud to be the first centre in New Zealand participating in the Phase 3 CoMpass clinical trial.
NewsMonday, 28 Jul 2025Auckland Eye Welcomes Cornea and Anterior Segment Specialist Dr Bia Kim
Auckland Eye is pleased to welcome Dr Bia Kim, a highly trained Cornea and Anterior Segment Specialist, to our team.
